{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "COVID-19",
      "SARS-CoV-2",
      "Vaccine"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "35042081",
  "DateCompleted": {
    "Year": "2022",
    "Month": "02",
    "Day": "01"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "02",
    "Day": "01"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2022",
        "Month": "01",
        "Day": "15"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "103811",
      "10.1016/j.ebiom.2021.103811",
      "S2352-3964(21)00605-8"
    ],
    "Journal": {
      "ISSN": "2352-3964",
      "JournalIssue": {
        "Volume": "75",
        "PubDate": {
          "Year": "2022",
          "Month": "Jan"
        }
      },
      "Title": "EBioMedicine",
      "ISOAbbreviation": "EBioMedicine"
    },
    "ArticleTitle": "Safety and immunogenicity of the measles vector-based SARS-CoV-2 vaccine candidate, V591, in adults: results from a phase 1/2 randomised, double-blind, placebo-controlled, dose-ranging trial.",
    "Pagination": {
      "StartPage": "103811",
      "MedlinePgn": "103811"
    },
    "Abstract": {
      "AbstractText": [
        "We report on the safety and immunogenicity of V591, a measles vector-based SARS-CoV-2 vaccine candidate.",
        "In this multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial, healthy adults with no history of COVID-19 disease were assigned to intramuscular injection of V591 or placebo (4:1 ratio). In part 1, younger adults (18-55 years) received V591 median tissue culture infectious dose (TCID<sub>50</sub>)-levels of 1\u00d710<sup>5</sup> or 1\u00d710<sup>6</sup> or placebo, 56 days apart. In part 2, younger and older (>55 years) adults received a single dose of one of four (10<sup>4</sup>/10<sup>5</sup>/10<sup>6</sup>/10<sup>7</sup>) or one of two (10<sup>5</sup>/10<sup>6</sup>) V591 TCID<sub>50</sub> levels, respectively, or placebo.",
        "safety/tolerability. Secondary outcome: humoral immunogenicity. ClinicalTrials.gov: NCT04498247.",
        "From August-December 2020, 444 participants were screened and 263 randomised (210 V591; 53 placebo); 262 received at least one and 10 received two doses of V591 or placebo. Adverse events were experienced by 140/209 (67.0%) V591 dose-group participants and 37/53 (69.8%) placebo-group participants following injection 1; most frequent were fatigue (57 [27.3%] vs 20 [37.7%]), headache (57 [27.3%] vs 19 [35.8%]), myalgia (35 [16.7%] vs 10 [18.9%]), and injection-site pain (35 [16.7%] vs 4 [7.5%]). No deaths nor vaccine-related serious adverse events occurred. At Day 29, no anti-SARS-CoV-2 spike serum neutralising antibody and IgG-responses were identified in placebo or the three lower V591 dose-groups; responses were detected with V591 1\u00d710<sup>7</sup> TCID<sub>50</sub>, although titres were lower than convalescent serum.",
        "V591 was generally well tolerated, but immunogenicity was insufficient to warrant continued development.",
        "Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA."
      ],
      "CopyrightInformation": "Copyright \u00a9 2022 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ USA, The Author(s). Published by Elsevier B.V. All rights reserved."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "SGS Life Sciences, Antwerp, Belgium."
          }
        ],
        "LastName": "Vanhoutte",
        "ForeName": "Fr\u00e9d\u00e9ric",
        "Initials": "F"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Merck & Co., Inc., Kenilworth, NJ, USA."
          }
        ],
        "LastName": "Liu",
        "ForeName": "Wen",
        "Initials": "W"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Merck & Co., Inc., Kenilworth, NJ, USA."
          }
        ],
        "LastName": "Wiedmann",
        "ForeName": "Richard T",
        "Initials": "RT"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Merck & Co., Inc., Kenilworth, NJ, USA."
          }
        ],
        "LastName": "Haspeslagh",
        "ForeName": "Liesbeth",
        "Initials": "L"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Merck & Co., Inc., Kenilworth, NJ, USA."
          }
        ],
        "LastName": "Cao",
        "ForeName": "Xin",
        "Initials": "X"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Merck & Co., Inc., Kenilworth, NJ, USA; Currently at AlloVir, Inc., Cambridge, MA, USA."
          }
        ],
        "LastName": "Boundy",
        "ForeName": "Keith",
        "Initials": "K"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Merck & Co., Inc., Kenilworth, NJ, USA; Currently at Flagship Pioneering, Boston, MA, USA."
          }
        ],
        "LastName": "Aliprantis",
        "ForeName": "Antonios",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Merck & Co., Inc., Kenilworth, NJ, USA."
          }
        ],
        "LastName": "Davila",
        "ForeName": "Michelle",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Merck & Co., Inc., Kenilworth, NJ, USA."
          }
        ],
        "LastName": "Hartzel",
        "ForeName": "Jonathan",
        "Initials": "J"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Merck & Co., Inc., Kenilworth, NJ, USA."
          }
        ],
        "LastName": "Li",
        "ForeName": "Jianing",
        "Initials": "J"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Merck & Co., Inc., Kenilworth, NJ, USA."
          }
        ],
        "LastName": "McGuire",
        "ForeName": "Mac",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Themis Bioscience GmbH, Vienna, Austria, a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA."
          }
        ],
        "LastName": "Ramsauer",
        "ForeName": "Katrin",
        "Initials": "K"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Themis Bioscience GmbH, Vienna, Austria, a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA."
          }
        ],
        "LastName": "Tomberger",
        "ForeName": "Yvonne",
        "Initials": "Y"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Themis Bioscience GmbH, Vienna, Austria, a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA."
          }
        ],
        "LastName": "Tschismarov",
        "ForeName": "Roland",
        "Initials": "R"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Merck & Co., Inc., Kenilworth, NJ, USA."
          }
        ],
        "LastName": "Brown",
        "ForeName": "Deborah D",
        "Initials": "DD"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Merck & Co., Inc., Kenilworth, NJ, USA."
          }
        ],
        "LastName": "Xu",
        "ForeName": "Weifeng",
        "Initials": "W"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Merck & Co., Inc., Kenilworth, NJ, USA."
          }
        ],
        "LastName": "Sachs",
        "ForeName": "Jeffrey R",
        "Initials": "JR"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Merck & Co., Inc., Kenilworth, NJ, USA."
          }
        ],
        "LastName": "Russell",
        "ForeName": "Kevin",
        "Initials": "K"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Merck & Co., Inc., Kenilworth, NJ, USA."
          }
        ],
        "LastName": "Stoch",
        "ForeName": "S Aubrey",
        "Initials": "SA"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Merck & Co., Inc., Kenilworth, NJ, USA. Electronic address: eseng_lai@merck.com."
          }
        ],
        "LastName": "Lai",
        "ForeName": "Eseng",
        "Initials": "E"
      }
    ],
    "DataBankList": [
      {
        "DataBankName": "ClinicalTrials.gov",
        "AccessionNumberList": [
          "NCT04498247"
        ]
      }
    ],
    "PublicationTypeList": [
      "Clinical Trial, Phase I",
      "Clinical Trial, Phase II",
      "Journal Article",
      "Multicenter Study",
      "Randomized Controlled Trial"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Netherlands",
    "MedlineTA": "EBioMedicine",
    "NlmUniqueID": "101647039",
    "ISSNLinking": "2352-3964"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "COVID-19 Vaccines"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Adolescent"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Adult"
    },
    {
      "QualifierName": [
        "genetics",
        "immunology",
        "prevention & control"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "genetics",
        "immunology"
      ],
      "DescriptorName": "COVID-19 Vaccines"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Double-Blind Method"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Genetic Vectors"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Immunogenicity, Vaccine"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Measles virus"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Middle Aged"
    },
    {
      "QualifierName": [
        "genetics",
        "immunology"
      ],
      "DescriptorName": "SARS-CoV-2"
    }
  ],
  "CoiStatement": "Declaration of interests WL, RTW, LH, XC, MD, JH, JL, MMcG, KR, YT, RT, DDB, WX, KR, SAS and EL are employees of Merck Sharpe & Dohme, Corp., and division of Merck & Co., Inc., Kenilworth, NJ, USA, and may own stock or hold stock options in the Company. JRS is an employee of Merck Sharpe & Dohme, Corp. and division of Merck & Co., Inc., Kenilworth, NJ, USA, holding stocks alongside stocks in various pharmaceutical and biotechnology companies and service providers, has participated on various editorial boards and committees for Society for Industrial and Applied Mathematics and is a member and participant in committees for the International Society of Pharmacometrics. KB was an employee of Merck Sharpe & Dohme, Corp., and division of Merck & Co., Inc., Kenilworth, NJ, USA until February 2021. AA was an employee of Merck Sharpe & Dohme, Corp., and division of Merck & Co., Inc., Kenilworth, NJ, USA, until September 2021. All other authors report no conflicts of interest."
}